Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P030017/S377

Precision Spinal Cord Stimulator (SCS) Systems

Boston Scientific Corp · Decision date Jan 21, 2026

FDA DECISIONP030017/S377

What did the FDA approve?

FDA records P030017/S377 as a supplement to PMA P030017, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Jan 21, 2026.

FDA approval order statement

Approval for the following changes related to the OR cables and extensions: 1) an alternate manufacturing site (i.e., Jiangyin SINBON Electronics Co. Ltd., FDA Establishment Identifier 3007616088), 2) dimensional changes, 3) change of material for two polyurethane components (i.e., strain relief and cable jacket) to a trademarked thermoplastic polyurethane (i.e., IROGRAN A75E 5040), and 4) removal of a duplicative cleaning step.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Neurology
Decision date
Jan 21, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P030017/S377
Regulatory pathway
PMA supplement
Product code
LGW
Decision code
APPR
Decision date
Jan 21, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.

Product code
LGW
FDA device class
3

For the original device and its historical approval scope, see PMA P030017. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P030017 · Original PMA

    PRECISION SPINAL CORD STIMULATION(SCS) SYSTEM

  2. P030017/S377 received

    Application receipt date recorded by FDA.

  3. P030017/S386 · Related supplement

    Precision Spinal Cord Stimulator (SCS) Systems

  4. P030017/S389 · Related supplement

    WaveWriter Alpha Prime Spinal Cord Stimulation (SCS) Systems

  5. P030017/S390 · Related supplement

    Precision Spinal Cord Stimulator (SCS) Systems

  6. P030017/S374 · Related supplement

    WaveWriter Alpha Spinal Cord Stimulator (SCS) Mixed Systems, M8 Adaptor

  7. P030017/S377 · FDA decision

    Normal 180 Day Track

  8. P030017/S391 · Related supplement

    Precision Spinal Cord Stimulator (SCS) Systems

  9. P030017/S387 · Related supplement

    Precision Spinal Cord Stimulator (SCS) Systems Introducer Hub Mold Change

  10. P030017/S394 · Related supplement

    Precision Spinal Cord Stimulator (SCS) Systems

  11. P030017/S395 · Related supplement

    Precision Spinal Cord Stimulator (SCS) Systems

  12. P030017/S392 · Related supplement

    Celestia Implantable Pulse Generator, Celestia External Trial Stimulator

  13. P030017/S393 · Related supplement

    Spinal Cord Stimulation (SCS)

  14. P030017/S397 · Related supplement

    Precision Spinal Cord Stimulator (SCS) Systems

  15. P030017/S398 · Related supplement

    Precision Spinal Cord Stimulator (SCS) Systems

  16. P030017/S396 · Related supplement

    WaveWriter Alpha and WaveWriter Alpha Prime SCS Systems; Celestia and Celestia Prime SCS Systems

  17. P030017/S399 · Related supplement

    Precision Spectra SCS Systems; Precision Novi SCS Systems; Precision Montage MRI SCS Systems; Spectra Wave Writer SCS Sy

Timeline entries are records held by MedtechLedger for P030017. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P030017

Product / regulatory recordCompanyPathwayDecision dateSource
Boston Scientific CorpPMA approvalApr 27, 2004FDA
Boston Scientific CorpPMA supplementSep 19, 2025FDA
Boston Scientific CorpPMA supplementDec 10, 2025FDA
Boston Scientific CorpPMA supplementDec 17, 2025FDA
Boston Scientific CorpPMA supplementDec 18, 2025FDA
Boston Scientific CorpPMA supplementJan 22, 2026FDA
Boston Scientific CorpPMA supplementFeb 11, 2026FDA
Boston Scientific CorpPMA supplementMay 13, 2026FDA
Boston Scientific CorpPMA supplementMay 18, 2026FDA
Boston Scientific CorpPMA supplementMay 21, 2026FDA
Boston Scientific CorpPMA supplementMay 28, 2026FDA
Boston Scientific CorpPMA supplementJul 10, 2026FDA
Boston Scientific CorpPMA supplementAug 10, 2026FDA
Boston Scientific CorpPMA supplementSep 9, 2026FDA
Boston Scientific CorpPMA supplementSep 22, 2026FDA

Explore the linked device profile

Other records with product code LGW

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corp

Headquarters
Not reported
FDA applicant address
25155 Rye Canyon Loop, Valencia, CA, 91355

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records